SCHEMBL1406217

SCHEMBL1406217

COc1ccc2cc(C(=O)NC(=O)c3ccc(O)c(C(=O)O)c3)c(=O)oc2c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 9/20 0.49
▸ HSD17B10 Q99714 1/20 0.48
▸ CA12 O43570 1/20 0.48
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ CA3 P07451 1/20 0.48
▸ CA4 P22748 1/20 0.48
▸ CA6 P23280 1/20 0.48
▸ CA5A P35218 1/20 0.48
▸ CA7 P43166 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ CA14 Q9ULX7 1/20 0.48
▸ CA5B Q9Y2D0 1/20 0.48
▸ MAPT P10636 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ GPR35 Q9HC97 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ MAOA P21397 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5087141 0.90 MAOA (0.49) CNR2HSD17B10CA12CA1CA2
SCHEMBL982766 0.82 CA12 (0.68) CNR2HSD17B10CA12CA1CA2
SCHEMBL1406666 0.82 MAOA (0.49) CNR2HSD17B10CA12CA1CA2
SCHEMBL1406450 0.81 GPR35 (0.49) HSD17B10CA12CA1CA2CA3
SCHEMBL1406341 0.80 SLC16A3 (0.65) HSD17B10CA12CA1CA2CA3
SCHEMBL1406194 0.80 GPR35 (0.48) HSD17B10CA12CA1CA2CA3
SCHEMBL1406413 0.76 CNR2 (0.44) CNR2HSD17B10CA12CA1CA2
SCHEMBL22129765 0.74 ALDH1A1 (0.59) CNR2HSD17B10CA12CA1CA2
SCHEMBL22132852 0.74 MEN1 (0.60) CNR2HSD17B10MAPTALDH1A1POLB
SCHEMBL1406745 0.73 GPR35 (0.52) HSD17B10CA12CA1CA2CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295053-B1 Novel 2H-chromen-2-one-3-carboxamides for medical uses INST MATERIA MEDICA CAMS (CN) 2016-10-19 — — EP disclosed
US-8338401-B2 Coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2012-12-25 — — US disclosed
EP-2295053-A1 Novel 2H-chromen-2-one-3-carboxamides for medical uses THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2011-03-16 — — EP disclosed
WO-2008013928-A2 TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR BIOGEN IDEC MA INC. (US) 2008-01-31 — — WO disclosed
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-07-06 — — US disclosed
EP-1570846-A1 THE NOVEL COUMARIN-AMIDE DERIVATIVES AND ITS PREPARATION, SAID DRUG COMPOSITION AND ITS USE THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2005-09-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSR, GLS, INSRR CNR2 350/4885HSD17B10 949/4885CA12 3153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback